IOTA Pharmaceuticals

Email Usinfo@iotapharma.com

IOTA Pharmaceuticals
Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
WINDOW on Glioblastoma
 
 
IOTA Pharmaceuticals
IOTA offers the following Screening Services:
 
Virtual screening packages
IOTA will perform a virtual screen on our proprietary “Diverse 60,000” virtual library using your chosen ligand-binding site as target, returning a “hit list” of the top 500 fragments to you from the virtual screen. Virtual hits from this screen can be progressed into screening options 2, 3, 4 and 5 below.
 
Surface Plasmon Resonance (SPR) screening package
IOTA has access to state-of-the-art SPR screening platforms. IOTA can screen any of its own libraries, or your proprietary libraries, using your target on this SPR platform. We can also arrange for the genetic engineering, expression, and purification of your target in industry-standard expression systems to provide sufficient material for SPR screening.
 
High-sensitivity biochemical screening package
IOTA routinely screens its own in-house targets, including kinases, proteases and GPCRs, with high-sensitivity biochemical fragment screens. We can arrange for your targets to be run in the same assays, or customize assays specifically for your targets, under confidentiality.
 
Nuclear Magnetic Resonance (NMR) screening package
Through the IOTA network, you also have access to state-of-the-art NMR screening. IOTA can screen any of its own libraries, or your proprietary libraries, using labelled targets on this NMR platform. We can also arrange for the genetic engineering, expression, and purification of labelled targets in industry-standard expression systems to provide sufficient material for NMR screening.
 
Co-crystallography of Fragment-based leads
Through the IOTA network, you also have access to state-of-the-art crystallographic analysis of fragment binding modes. Through its partners, IOTA can screen hits from any of its own libraries, or your proprietary libraries, or your single compounds of interest, using soaking experiments with a range of crystal targets.
 

Contact IOTA’s Business Development group at info@iotapharma.com for further details of these screening services.

RSS